SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 31 Issue: 2

CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population

Türk popülasyonunda Polisitemia vera hastalarında CYP 2D6*4 polimorfizmi

Zehra Okat
Kezban Uçar Çiftçi
Kübra Yaman
Selina Toplayıcı
Elif Kurt
Yavuz Taga
Pages
—
Publication Date
2018-06-05
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: Many studies have shown the association of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Many studies have shown the association of
📊
Key Findings & Data:Objective: Many studies have shown the association of
💡
Conclusion & Impact:Objective: Many studies have shown the association of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cytochrome P450 2D6 · Genetic polymorphism · Polycythemia vera (PV)

Abstract

Objective: Many studies have shown the association of

Özet

Amaç: Birçok çalışma, ksenobiyotiklerin biyotransformasyonundan

🔖

Cite This Article

Okat, Z., Çiftçi, K. U., Yaman, K., Toplayıcı, S., Kurt, E., Taga, Y. (2018). CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population. Marmara Medical Journal, Volume: 31 Issue: 2. https://doi.org/10.5472/marumj.430790

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (49)

  1. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33:313-20. doi: 10.1055/s-2007-976165.
  2. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2003; 200-24. doi: 10.1182/ asheducation-2003.1.200.
  3. Tefferi A. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Seminars in Hematology 1999; 36:3–8.
  4. Bilgrami S, Greenberg, B R. Polycythemia rubra vera. Semin Oncol 1995; 22:307-26.
  5. Samuelsson J. Survival in a patient with polycthemia vera for over thirty years: implications for treatment decisions in younger patients. Leukemia and Lymphoma 1998; 32:195-8. doi: 10.3109/10428199809059262.
  6. Gonzalez FJ, Tukey RH, (editors). Drug Metabolism: How Humans Cope with Exposure to Xenobiotics.” Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, 2012.
  7. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008; 21:70-83. doi: 10.1021/tx700079z.
  8. Bock KW, Lilienblum W, Fischer G, et al. The role of conjugation reactions in detoxication. Arch Toxicol 1987; 60:22-29.
  9. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154:103-16.
  10. Abraham JE, Maranian MJ, Driver KE, et al. CYP 2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64. doi: 10.1186/bcr2629.
  11. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13:434-9.
  12. Bertilsson L, Dahl ML, Dalén P and Al-Shurbaji A. Molecular genetics of CYP 2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53:111-22. doi: 10.1046/j.0306-5251.2001.01548.x.
  13. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-95.
  14. Hanioka N, Kimura S, Meyer UA, et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP 2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet 1990; 47:994-1001.
  15. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression,enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 2013; 138:103-41. doi: 10.1016/j. pharmthera.2012.12.007.
  16. Bertilsson L, Dahl ML, Sjo¨qvist F, et al. Molecular basis for rational megaprescribing inultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63.
  17. Christensen РМ, Gotzsche PC, Brosen K. The sparteine/ debrisoquine (CYP 2D6) oxidation polymorphism and the risk of lung cancer: a metaanalysis. Eur J Clin Pharmacol 1997; 51:389-93. doi: 10.1007/s002280050219.
  18. Taninghera M, Malacarnea D, Ugolinia A, et al. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutation Research/Reviews in Mutation Research 1999; 436:227–61.
  19. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990; 50:7415-21.
  20. Schur BC, Bjerke J, Nuwayhid N, et al. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR*. Clinica Chimica Acta 2001; 308:25-31. doi: 10.1016/ S0009-8981(01)00422-3.
  21. Kim JW, Lee CG, Park YG, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer 2000; 88:2082-91. doi: 10.1002/(SICI)1097-0142(20000501)88:9 3.0.CO;2-D.
  22. Morgan GJ, Smith MT. Metabolic enzyme polymorphisms and susceptibility to acute leukemia in adults. Am J Pharmacogenomics 2002; 2(2).
  23. Hatagima, A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad. Saúde Pública Rio de Janeiro 2002; 18:357-77.
  24. Anwar WA, Abdel-Rahman SZ, El-Zein RA, et al. Genetic polymorphism of GSTM1, CYP2E1 and CYP 2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996; 17: 1923-29.
  25. Caporaso NE, Tucker MA, Hoover RN, et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990; 82:1264-72.
  26. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P4502D6 (CYP 2D6): clinical consequences, evolutionary aspects and functional diversity, The Pharmacogenomics J 2005; 5:6 – 13. doi:10.1038/ sj.tpj.6500285.
  27. Roddam PL, Rollinson S, Kane E, et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia, Pharmacogenetics 2000; 10:605-15.
  28. Worrall SF, Corrigan M, High A, et al. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP 2D6. Pharmacogenetics 1998; 8:433-9.
  29. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 1992; 339:1375–7.
  30. Sarmanova J, Benesova K, Gut I, et al. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin’s and non-Hodgkin’s lymphomas. Hum Mol Genet 2001;10:1265- 73.
  31. Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, et al. Role of CYP 2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 2006;81:162-70. doi: 10.1002/ajh.20434.
  32. Sailaja K, Vishnupriya S, Surekha D, et al. Association of CYP 2D6* 4 Polymorphism with Chronic Myeloid Leukemia. Journal of Medical Sciences Research 2007; 1(1).
  33. Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP 2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999; 20: 1225- 9.
  34. Tayser KE, Ehsan G, Ghonemy EE, et al. Study of genetic polymorphism of xenobiotic enzymes in acute leukemia. Blood Coagulation and Fibrionolysis 2007; 18:489-95. doi: 10.1097/MBC.0b013e3281eec930.
  35. Joseph T, Kusumakkumary P, Chacko P, et al. Genetic polymorphism of CYP1A1, CYP 2D6, GSTM1and GSTT1 and susceptibility to acute lymphoblasticleukaemia in Indian children. Pediatric Blood Cancer 2004; 43:560 – 67. doi: 10.1002/pbc.20074.
  36. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: ınfluence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999; 93: 1496-501.
  37. Marsh JCW, Choudry J, Parry-Jones N, et al. Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia. Br J Haematol 1999; 104:266-70.
  38. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemisry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:23-37. doi: 10.1007/s00210-003-0832-2.
  39. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-7.
  40. Aydin M, Hatirnaz O, Erensoy N, et al. CYP 2D6 and CYP1A1 mutations in the Turkish population.Cell Biochem Funct 2005; 23:133-5. doi: 10.1002/cbf.1222.
  41. Koseler A, Ilcol YO, Ulus IH. Frequency of mutated allele CYP 2D6* 4 in the Turkish population. Pharmacology 2007; 79:203-06. doi: 10.1159/000100959.
  42. Aynacıoğlu AS, Sachse C, Bozkurt A. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66: 185-92. doi: 10.1053/cp.1999.v66.100072001.
  43. Sahin S, Aydogan L, Benli I, et al. Distribution of HLA-B27 and CYP 2D6* 4 mutations in the middle Black Sea area (Tokat) of Turkey. Genetics and Molecular Research 2011 10:3987-91. doi: 10.4238/2011.December.2.3
  44. Hardy GH. Mendelian proportions in a mixed population. Science 1908; 28:49-50. doi: 10.1126/science.28.706.49
  45. Rodriguez S, Gaunt TR, Day IN. Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169:505-14. doi: 10.1093/aje/kwn359.
  46. Anderson LA, Duncombe AS, Hughes M, et al. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 2012;87:175-82. doi: 10.1002/ajh.22212.
  47. Ozawa S. Drug-Drug Interactions with consideration of pharmacogenetics. Yakugaku zasshi Journal of the Pharmaceutical Society of Japan. 2018;138:365-71. doi: 10.1248/yakushi.17-00191-5.
  48. Thota K, Prasad K, Basaveswara Rao MV. Detection of cytochrome P450 polymorphisms in breast cancer patients may ımpact on tamoxifen therapy. Asian Pac J Cancer Prev 2018 26;19:343-50. doi: 10.22034/APJCP.2018.19.2.343.
  49. Anderson LA, Duncombe AS, Hughes M, et al. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 2012;87:175-82. doi: 10.1002/ajh.22212.